Pediatrix Medical Group, Inc. (NYSE:MD) Shares Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC grew its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 639.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 290,336 shares of the company’s stock after purchasing an additional 251,072 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.34% of Pediatrix Medical Group worth $2,192,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of MD. Rubric Capital Management LP lifted its stake in shares of Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the period. Invenomic Capital Management LP increased its holdings in Pediatrix Medical Group by 93.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock valued at $12,815,000 after buying an additional 664,955 shares in the last quarter. Boston Partners lifted its position in shares of Pediatrix Medical Group by 34.0% during the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares during the period. ClariVest Asset Management LLC purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $1,721,000. Finally, Vanguard Group Inc. grew its holdings in shares of Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after acquiring an additional 164,333 shares during the period. 97.71% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on MD shares. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft raised shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price objective on the stock in a research note on Friday, June 7th. Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and lifted their target price for the stock from $8.00 to $14.00 in a research report on Thursday, September 26th. Truist Financial increased their price target on shares of Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, UBS Group raised their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.30.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the transaction, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at $1,834,310.79. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,100 shares of company stock worth $701,889. 2.00% of the stock is owned by company insiders.

Pediatrix Medical Group Stock Performance

NYSE:MD opened at $11.60 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a market cap of $976.11 million, a PE ratio of -13.65, a P/E/G ratio of 1.64 and a beta of 1.56. The firm has a 50 day simple moving average of $10.12 and a 200-day simple moving average of $8.90. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $13.01.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The company had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. During the same period in the previous year, the firm posted $0.37 EPS. Pediatrix Medical Group’s revenue was up .7% on a year-over-year basis. On average, equities analysts expect that Pediatrix Medical Group, Inc. will post 1.19 EPS for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.